In vitro activity of Cacicol ® on herpes simplex virus type 1: a promising adjunct therapy of herpetic corneal infections?

ConclusionsCacicol® has a significant in vitro antiherpetic activity and seems particularly interesting for the management of HSV‐1 resistant to acyclovir or foscarnet, especially in tissues that can receive Cacicol® by topical application (such as the cornea). Clinical studies are necessary to determine its in vivo activity and its usefulness as a promising adjunct or alternative therapy of recurrent HSK.

Source: Acta Ophthalmologica - September 13, 2016 Category: Opthalmology Authors: M. Labetoulle, A. Rousseau, M. Breckler, L. Molet, D. Boutolleau, S. Burrel, C. Deback Tags: Abstracts from the 2016 European Association for Vision and Eye Research Conference Source Type: research